Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Citius Oncology, Inc.

NASDAQ: CTOR · Life Sciences · 4 alerts · CIK 1851484

Share price
$0.5350Close, Nov 16
Market cap
$49.7M
Shares outstanding
92.98MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Citius Oncology, Inc. filings on SEC EDGAR ↗

4:32 PM ET 8-K
Clinical Trial Data

Citius Oncology Clinical Trial Data

Citius Oncology announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. Data presented at the EORTC-CLTG 2026 Annual Meeting showed that patients who responded to treatment reported sustained improvements in skin-related quality of life and significant reductions in pruritus (itching).

4:06 PM ET 8-K
Business Update

Citius Oncology Business Update

Citius Oncology reported preliminary fiscal fourth quarter 2026 operational metrics for its drug LYMPHIR, showing a 120% increase in unit sales to U.S. wholesalers compared to the prior quarter. The company reached 792 units sold to wholesalers and expanded its institutional reach to 54 prescribing centers as of late October.

Term
Q4 2026
4:10 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Citius Oncology Nasdaq/NYSE Compliance Notice

Citius Oncology received a formal extension from Nasdaq until April 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. To satisfy the rule, the company's common stock must close at or above $1.00 for at least ten consecutive business days. The stock continues to trade on the Nasdaq Capital Market under the symbol 'CTOR' while the company evaluates options to address the deficiency.

Counterparty
Nasdaq Stock Market LLC
Term
through April 19, 2027
4:31 PM ET 8-K
Shareholder Meeting

Citius Oncology Shareholder Meeting

Citius Oncology, Inc. held its 2026 Annual Meeting of Stockholders on September 29, 2026. Stockholders elected three Class II directors (Dr. Eugene Holuka, Robert Smith, and Carol Webb) for three-year terms and ratified Wolf & Company, P.C. as the company's independent registered public accounting firm for the fiscal year ending September 30, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.